Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Sarcoma 1Pancreatic Neoplasms 1Neoplasms, Plasma Cell 1Myeloproliferative Disorders 1Myelodysplastic-Myeloproliferative Diseases 1Myelodysplastic Syndromes 1Multiple Myeloma 1Meningioma 1Leukemia, Myelomonocytic, Chronic 1Leukemia 1Hemangiopericytoma, Malignant 1Central Nervous System Neoplasms 1Brain Neoplasms 1Anemia, Refractory, with Excess of Blasts 1Anemia, Refractory 1

Interventions

Gemcitabine 153Fluorouracil 45Capecitabine 45130-nm albumin-bound paclitaxel 43Oxaliplatin 42Albumin-Bound Paclitaxel 39Leucovorin 31Erlotinib Hydrochloride 30pembrolizumab 23Radiotherapy 22Irinotecan 22Radiosurgery 20Bevacizumab 19Docetaxel 17Cyclophosphamide 17Taxes 13Cisplatin 13Cetuximab 13folfirinox 12Nivolumab 11Surgical Procedures, Operative 7Paclitaxel 7Ipilimumab 7dehydroftorafur 6Standard of Care 6Radiation 6Magnetic Resonance Spectroscopy 6spartalizumab 5ruxolitinib 5durvalumab 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Pancreatic Neoplasms × vatalanib × Clear all
NCT00185588 2014-09-15

Phase 1-2 Vatalanib and Gemcitabine in Advanced Pancreatic Cancer

Stanford University

Phase 1/2 Completed
33 enrolled 10 charts
Gastrointestinal

Pancreatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡